Prostate Gland Diseases in Sierra Leone: A Histopathological Study

Main Article Content

N. T. Onyishi
A. A. Sesay
A. Kalawa
M. Bah
T. B. Kamara
T. Davies
L. Gordon-Harris
B. M. Duduyemi

Abstract

Background: Prostate diseases pose a huge burden on adult males across all populations. Prostate cancer, for instance, has been the most frequent cancer type and the third most common cause of cancer death in males in low-/medium sociodemographic index (SDI) countries as well as the 21st leading cause of death, overall, in men. Since it is recognized that diseases often showed geographic variations in manifestation, this preliminary study aims to document the types and patterns of prostate pathologies found in histological biopsies in Sierra Leone.


Materials and Methods: The study was a four-year retrospective review of prostate gland specimens received in the pathology laboratory of Connaught Hospital, Freetown. The electronic archived reports and specimen reception register were used to extract data regarding patient's age, specimen type and histopathological diagnosis into an Excel spreadsheet, cleaned and then imported into R statistical software for analysis using ggplot2 and flextable packages. Results were presented in tables of frequencies and bar charts. For statistical tests, p-value of 0.05 was accepted as statistically significant.


Results: Four hundred and nineteen (419) prostate gland samples were received and processed over four years. Of these, 18.1% (76/419) were open prostatectomies, while 81.9% (343/419) were trucut samples. Two hundred and fifty-nine (259) cases were benign and 153 malignant. The most common lesion was BPH (57.1%) followed by adenocarcinoma (36.3%)


Conclusion: Prostate disease is relatively common in Sierra Leone with the age of occurrence same with established trends in other countries of the West African subregion. Benign prostate hyperplasia is the most common prostate disease followed by adenocarcinoma of the prostate.


  

Downloads

Download data is not yet available.

Article Details

Section

Original Articles

How to Cite

Onyishi, N. T., Sesay, A. A., Kalawa, A., Bah, M., Kamara, T. B., Davies, T., Gordon-Harris, L., & Duduyemi, B. M. (2025). Prostate Gland Diseases in Sierra Leone: A Histopathological Study. Annals of Laboratory and Clinical Medicine, 1(1), 10-14. https://doi.org/10.82216/alcm.vol1no1.2

References

Singh O, Bolla SR. Anatomy, Abdomen and Pelvis, Prostate. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Mar 19]. Available from: http://www.ncbi.nlm.nih. gov/ books/NBK540987/

Prostate Problems - NIDDK [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. [cited 2025 Mar 19]. Available from:

https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CACancer J Clin. 2024;74(3):22963.

Prostate cancer - Level 3 cause | Institute for Health Metrics and Evaluation [Internet]. [cited 2025 Mar 19]. Available from: https://www.healthdata.org/research-analysis/diseases-injuriesrisks/factsheets/2021-prostate-cancer-level-3-disease.

Zi H, Liu MY, Luo LS, Huang Q, Luo PC, Luan HH, et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis,

bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res. 2024 Sep 18;11(1):64.

Zhang W, Cao G, Wu F, Wang Y, Liu Z, Hu H, et al. Global Burden of Prostate Cancer and Association with Socioeconomic Status, 19902019: A Systematic Analysis from the Global Burden of Disease Study. J Epidemiol Glob Health. 2023 May 6;13(3):40721.

Benign prostatic hyperplasia - Level 4 cause | Institute for Health Metrics and Evaluation [Internet]. [cited 2025 Mar 19]. Available from: https://www.healthdata.org/research-analysis/diseases-injuries-risks/factsheets/2021- benign-prostatic-hyperplasia-level-4.

Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022 Nov 1;3(11):e75476.

Chen X, Yang S, He Z, Chen Z, Tang X, Lin Y, et al. Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021. Sci Rep. 2025 Feb 15;15(1):5644.

James ND, Tannock I, NDow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet. 2024 Apr 27;403(10437):1683722.

Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) focus on the UK. BJU Int. 2015 Apr;115(4):50819.

Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002 Feb;59(2):24550.

Sagnier PP, MacFarlane G, Teillac P, Botto H, Richard F, Boyle P. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol. 1995 Mar;153(3 Pt 1):66973.

Ruiz M. Geography of Disease [Internet]. Oxford bibilographies. [cited 2025 Mar 22]. Available from: https://www.oxfordbibliographies.com/ display/document/obo-9780199874002/obo- 9780199874002-0153.xml

Liu TT, Thomas S, Mclean DT, Roldan-Alzate A, Hernando D, Ricke EA, et al. Prostate enlargement and altered urinary function are part of the aging process. Aging. 2019 May 13;11(9):265369.

IARC. Global Cancer Observatory [Internet]. [cited 2025 Mar25]. Available from: https://gco.iarc.fr/

Nwafor CC, Keshinro OS, Abudu EK. A histopathological study of prostate lesions in Lagos, Nigeria: A private practice experience.

Niger Med JJ Niger Med Assoc. 2015;56(5):33843.

Abubakar A, Alhaji SA, Sanusi HM, Aliyu S, Musa MU, Abdullahi AS. Histopathological Pattern of Prostatic Lesions in Kano, Northwestern Nigeria: A14 - Year Review. Ann Trop Pathol. 2019;10(2):1504.

Anunobi C, Akinde O, Elesha S, Daramola A, Tijani K, Ojewola R. Prostate diseases in Lagos, Nigeria: A histologic study with tPSA correlation. Niger Postgrad Med J. 2011 Jun 1;18:98104.

Cassell A, Yunusa B, Jalloh M, Mbodji MM, Diallo A, Ndoye M, et al. A Review of Localized Prostate Cancer: An African Perspective. World J Oncol. 2019;10(45):1628.

Garg M, Kaur G, Malhotra V, Garg R. Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions. Prostate Int. 2013 Dec 1;1(4):14651.

El-Karak F, Shamseddine A, Omar A, Haddad I, Abdelgawad M, Al Naqqash M, et al. Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study. ecancermedicalscience [Internet]. 2024 Apr 16 [cited 2025 Mar 15];18. Available from: https://ecancer.org/en/journal/ article/ 1695 - prostate- cancer- across- four- countries-in-the-middle-east-a-multi-centre- observational-retrospective-and-prognostic-study.

Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging. J Urol [Internet]. 2009 Oct [cited 2025 Mar 25]; Available from: https://www.auajournals.org/doi/10.1016/j.juro.20 09.06.047.

Li SH, Yang QF, Zuo PY, Liu YW, Liao YH, Liu CY. Prostate volume growth rate changes over time: Results from men 18 to 92 years old in a longitudinal community-based study. J Huazhong Univ Sci Technol. 2016 Dec;36(6):796800.

Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms. Urol Clin North Am. 2016 Aug;43(3):28997.

Jain MA, Leslie SW, Sapra A. Prostate Cancer Screening. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 20 25 Mar 31]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK556081/

Hugosson J. Population- based Screening for Prostate Cancer: Is it Time? Eur Urol. 2025 Mar 1;87(3):3401.